TECHNOLOGY PLATFORM

With our technology platform, we are able to develop a pipeline that target different growth factors to treat different solid tumours

Technology Platform

We design synthetic therapeutics that include immunogenic sequence of growth factors domain that are expressed with a synthetic carrier.

Growth factors are natural occurring proteins that are recognized by the body that will not normally be targeted by the body’s immune system. We have developed a proprietary platform that can create synthetic molecules that stimulate an antibody response targeting specific growth factors proteins active in tumour proliferation.

Our innovative approach allows us to develop novel mono- or bi-specific therapeutics, in order to treat cancers which are often controlled by multiple growth factor-triggered pathways.

Monomeric

Single targeted synthetic molecule

1. We take a part of the targeted growth factor gene

2. Infused with a carrier protein it is then fused onto a plasmid

3. A monomeric synthetic molecule is expressed in a bacteria host

Bi-specific

Multi targeted synthetic molecule

1. Using 2 targeted growth factors genes

2. Both are infused with a carrier protein then fused to a plasmid

3. A bi-specific synthetic molecule is expressed in a bacteria host

Focusing on pathways that are active in tumour proliferation, In3Bio has created a robust and diversified pipeline of novel therapeutics addressing multiple indications.

Our pipeline contains both single and bi-specific molecules targeting different pathways active in solid tumours. Our width and strength enable us to create potential solutions for different cancer indications

Single Target Molecules

INO1

IN03

IN04

IN0X

Bi-Specific Molecules

INOX

IN0X

IN02

Patents

In3Bio has filed and been granted patent applications, including Patent Cooperation Treaties (PCTs), and nationalized patents. The protection of the intellectual property covers the United States, Europe, Japan, China, Australia and other countries.

The company has comprehensive team of scientist and lawyers who are responsible for the patents filing. Our legal teams are based in Boston, USA, and London, UK.

The company has granted patent for its platform technology and broad portfolio of growth factor targets